Feiba (anti-inhibitor coagulant complex) / Takeda - LARVOL DELTA

A miniaturized chemiluminescent thrombin generation assay to assess the effect of APCC in persons with hemophilia A with inhibitors: an observational study. (PubMed, Res Pract Thromb Haemost) - "To assess the performance of a novel microfluidic chemiluminescent TGA (microfluidic-TGAlum) to monitor the effect of anti-inhibitor coagulant complex (APCC) in persons with hemophilia A with inhibitors...Assay-specific differences in TGA response may complicate APCC monitoring in persons with hemophilia A with inhibitors. Our findings underscore the need for further mechanistic TGA studies and standardization."

Journal • Observational data • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Factor Concentrates for the Treatment of Acquired Coagulopathy in Patients With Left Ventricular Assist Devices: A Systematic Review. (PubMed, J Cardiothorac Vasc Anesth) - "In this context, rFVIIa was associated with a dose-dependent risk of thrombosis. Overall, PCC-based hemostatic management in LVAD patients appears reasonable; however, it is not currently possible to judge the safety of low-dose rVIIa or FEIBA."

Journal • Review • Cardiovascular • Hematological Disorders • Thrombosis • Transplantation

A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens. (PubMed, Pharmacy (Basel)) - "The optimal fixed-dose strategy for managing warfarin-associated hemorrhages remains unknown and few studies have evaluated the use of Factor VIII Inhibitor Bypass Activity (FEIBA). Among patients with a baseline INR ≥ 10, significantly more patients in the new group achieved a post-FEIBA INR ≤ 1.5 compared to the old group (86% vs. 17%, respectively). These findings suggest that the new FEIBA dosing regimen may improve INR reversal compared with the previous regimen, particularly among patients with a baseline INR ≥ 10, but larger studies are needed to confirm this observation."

Journal • Retrospective data • Hematological Disorders

Balancing Hemorrhage and Thrombosis: FEIBA Use in a Polytrauma Patient with Acute HIT (ASA 2026) - "Management required strict heparin avoidance, temporary interruption and reversal of argatroban and apixaban, invasive hemodynamic monitoring, vasopressor support, blood transfusion, and urgent administration of FEIBA as a heparin-free prohemostatic agent to reverse apixaban. Following hemostasis, antithrombotic therapy was carefully reinitiated to minimize the risk of stent thrombosis. This case highlights the anesthetic challenge of balancing catastrophic hemorrhage and extreme thrombotic risk in acute HIT, while emphasizing FEIBA (Anti-inhibitor coagulant complex) as an underrecognized reversal option."

Clinical • Cardiovascular • Hematological Disorders • Thrombosis

Efficacy of Recombinant Porcine Factor VIII for Acute Bleeding in Patients with Acquired Haemophilia A (AHA) (ISTH 2026) - "Treatment was successful in 34 patients (57%), while additional therapy was required in the remaining cases: recombinant activated coagulation factor VII (rFVIIa) in 10 cases, activated prothrombin complex concentrates (aPCC, FEIBA) in 6 cases, both agents in 6 cases, and in 10 cases therapy was ultimately switched to emicizumab...Second-line therapy included cyclophosphamide in 6 patients and anti-CD20 therapy in 6 patients...These findings highlight the importance of individualized, adaptive treatment strategies in managing AHA. DOI*10.1016/j.rpth.2026.104765"

Preclinical • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Infectious Disease • Rare Diseases • Septic Shock

Surgery in people with hemophilia A with factor VIII inhibitors in emicizumab prophylaxis: the real-world experience of a single center in a middle-income country. (ISTH 2026) - "He received treatment with FEIBA...Conclusions Surgery can be saftly performed with an adjusted dosage of factor VII with tranexamic acid as an adjuvant, without life-threatening hemorrhagic events...Importantly, no thrombotic complications or deaths occur. Table or Figure Upload (1) Page 2 Table or Figure Upload (2) DOI*10.1016/j.rpth.2026.104372"

Clinical • Real-world • Real-world evidence • Surgery • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Infectious Disease • Nephrology • Orthopedics • Rare Diseases • Thrombosis

Acquired haemophilia A in the setting of newly diagnosed non-metastatic gastroesophageal carcinoma – a case report (ISTH 2026) - "The patient had a history of coronary and peripheral artery disease and was on anticoagulant therapy with rivaroxaban...Ten days after rituximab administration, a single dose of 75 U/Kg of FVIII inhibitor bypassing activity (FEIBA) was delivered immediately before tumour removal via laparotomy. Early postoperative period was without excessive bleeding on the drainage sites and dalteparin prophylaxis of 5000 IU per day was maintained...One month later, warfarin was introduced by the general practitioner. Conclusions in the case of non-metastatic tumour and acquired haemophilia A, early operative management could be beneficial as a therapeutic method of resolving the underlying cause of secondary haemophilia. Table or Figure Upload (1) Laboratory parameters of oncology patient with acquired haemophilia A Page 2 DOI*10.1016/j.rpth.2026.106553"

Case report • Clinical • Metastases • Cardiovascular • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Hemophilia • Hemophilia A • Oncology • Peripheral Arterial Disease • Rare Diseases • Solid Tumor

Evaluation of Commercially Available Bypassing Strategies for Long-Acting Factor XI Antibodies (ISTH 2026) - "Methods Bypass of gruticibart (AB023 A2 ), AB011 A3 , and osocimab was tested using commercially available bypass agents NovoSeven® (recombinant factor VIIa), FEIBA® (activated PCC), and Kcentra® (non-activated PCC). Together, these findings suggest that FXI-directed anticoagulation may be clinically manageable with commercially available bypassing agents used at carefully controlled doses. DOI*10.1016/j.rpth.2026.105554"

Intracranial haemorrhage in a woman with mild haemophilia Α complicated by factor VIII inhibitor development (ISTH 2026) - "She received tranexamic acid and plasma-derived FVIII/VWF concentrates, then recombinant FVIII once the assay results were available...Recombinant FVIII was discontinued and a bypassing agent (FEIBA) was initiated...Following multidisciplinary discussion, rituximab (375mg/m2 weekly x 4) and emicizumab were commenced...Table or Figure Upload (1) Figure 1. Pedigree Page 2 DOI*10.1016/j.rpth.2026.106555"

Clinical • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Hemophilia • Hemophilia A • Hypertension • Postpartum Hemorrhage • Rare Diseases • F8

From bleeding to disease control: the central role of treating the underlying disease in Acquired Hemophilia A (ISTH 2026) - "Results The patient received anti-inhibitor coagulant complex (FEIBA®), as a bypassing agent and prednisone for immunosuppression, resulting in stable hemoglobin levels and hematoma regression, with gradual recovery of FVIII activity and a reduction in inhibitor titter (Table 1). (B) Open-mouth view showing a soft-palate hematoma with cervical ecchymosis. DOI*10.1016/j.rpth.2026.106550"

Genito-urinary Cancer • Hemophilia • Hemophilia A • Immunology • Rare Diseases • Renal Cell Carcinoma • Solid Tumor

Preclinical Safety and Thrombotic Risk Assessment of the siRNA TGM-148 for Bleeding Disorders (ISTH 2026) - "mTGM- 148 was co-administered with standard factor replacement therapies (Advate, BeneFIX) or bypassing agents (NovoSeven, FEIBA), with measurement of D-dimer levels. TGM-148 is advancing toward CTA submission in 2026. DOI*10.1016/j.rpth.2026.104873"

Preclinical • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases • Thrombosis

Aquired hemophilia A in a 5 years old Swedish boy (ISTH 2026) - "Prophylactic FEIBA 50 IU/kg thrice weekly was administered for 3 weeks...Prednisone was gradually tapered and no additional immunosuppressive agents were used... prolonged APTT 70 s (ref. 30-42), normal INR and platelet count, FVIII:C 4 IU/dL, FIX:C 76 IU/dL. Preliminary diagnosis was moderate congenital hemophilia A. He was successfully treated with blood transfusion, tranexamic acid and bolus doses of recombinant FVIII concentrate."

Hematological Disorders • Hemophilia • Hemophilia A • Infectious Disease • Mood Disorders • Rare Diseases

Thrombotic Outcomes Associated With Factor Eight Inhibitor Bypassing Activity Use in Neonatal and Infant Cardiac Surgery Including the Norwood Procedure: A Propensity Score‒Matched Analysis. (PubMed, J Cardiothorac Vasc Anesth) - "This study found that FEIBA use was not associated with a statistically significant increase in postoperative thrombosis in neonates and infants after cardiac surgery. Though patients undergoing the Norwood procedure had a 2-fold (nonsignificant) increase in catheter-associated thrombosis, we found no increase in the rate of shunt thrombosis or intervention."

Journal • Cardiovascular • Hematological Disorders • Pediatrics • Thrombosis

WHEN HYPOCOAGULABILITY MEETS THROMBOSIS: A SINGLE-CENTER COMPARATIVE STUDY OF CONGENITAL AND ACQUIRED PROTHROMBIN DEFICIENCY (EHA 2026) - "Prophylaxis treatment included prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) in 26.8% or tranexamic acid (TXA) alone in 24.4%. Acute bleeding was managed with PCC or, FFP or FEIBA in 31.7%, TXA alone in 12.2%, or none in 65.9%...Acquired type are more commonly associated with thrombotic events ,especially when accompanied by autoimmune disorders or malignancy , whereas congenital deficiency typically presents earlier in life with more severe bleeding phenotypes, despite the well-recognized discordance between factor levels and clinical severity. These distinctions underscore the importance of individualized evaluation and management strategies that address underlying etiologies as well as the concurrent risks of bleeding and thrombosis."

Clinical • Cardiovascular • Hepatology • Immunology • Thrombosis

First Successful Bloodless Combined Heart-Liver Transplantation in a Jehovah's Witness. (PubMed, Clin Transplant) - "This report expands the scope of bloodless medicine, offering a model for managing complex multi-organ transplants in patients with religious restrictions to blood products, with the patient continuing to exhibit excellent recovery approximately ten months post-transplant."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Fibrosis • Heart Failure • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Solid Organ Transplantation • Transplant Rejection • Transplantation

Refractory Hemorrhage Following Total Knee Replacement Unmasking Acquired Hemophilia A. (PubMed, Cureus) - "Hemostasis was achieved following treatment with FEIBA and NovoSeven under hematology guidance. This case highlights acquired hemophilia A as a rare but important differential diagnosis in persistent postoperative bleeding following total knee replacement. Early recognition, prompt coagulation workup, and multidisciplinary management are essential to improve outcomes."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Musculoskeletal Diseases • Orthopedics • Pain • Rare Diseases • Rheumatology

Acquired Hemophilia A (AHA) Associated With Malignancy and Antiphospholipid Antibodies: Two Case Reports With Distinct Etiologies. (PubMed, Cureus) - "He was treated with recombinant factor VII, corticosteroids, and cyclophosphamide, achieving clinical and laboratory improvement...Management requires a dual approach that targets bleeding control and inhibitor eradication, along with treatment of underlying conditions. Awareness of overlapping disorders, particularly in patients with antiphospholipid antibodies, is important for guiding appropriate management and improving outcomes."

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Infectious Disease • Oncology • Rare Diseases

A Rare Case With Severe and Refractory Emicizumab Hypersensitivity (ASPHO 2026) - "Despite premedication with diphenhydramine, famotidine, and hydrocortisone, severe delayed reactions occurred, necessitating permanent discontinuation. Bleeding episodes were managed with bypassing agents (anti-inhibitor coagulant complex, recombinant activated factor VII). ITI with simoctocog alfa achieved suboptimal response (peak inhibitor 84 BU; FVIII recovery 10%–25%) and was complicated by MRSA bacteremia, requiring discontinuation. Efanesoctocog alfa provided partial control with persistent high-titer inhibitors... This case documents rare severe emicizumab hypersensitivity refractory to premedication in a pediatric patient with high-responding inhibitor. When first-line non-factor therapies fail and ITI is unsuccessful, concizumab demonstrated substantial efficacy as alternative prophylaxis. Further investigation is needed to characterize risk factors for severe emicizumab reactions and establish management algorithms when standard therapies are not tolerated in..."

Clinical • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Rare Diseases

Apixaban Overdose with Massive Bleeding and Anti-Xa Levels. (PubMed, J Med Toxicol) - "Bleeding from an overdose of factor Xa inhibitors is a relatively rare occurrence; however, this case illustrates that life threatening hemorrhage can occur and may require aggressive supportive care. Anti-Xa levels demonstrated a first order pattern of elimination even at markedly supratherapeutic concentrations, consistent with several prior case reports."

Journal • CNS Disorders • Hematological Disorders

Detection of Early Symptomatic Seizures After Acute ICH With Point-of-Care EEG: A Case Report (SCCM 2026) - "(2025) proposed the introduction of a point-of-care (POC) EEG system into the stroke-code workflow to enhance differential diagnosis and to monitor for seizures in high-risk patients.Description: A 92-year-old male with past history of atrial fibrillation on rivaroxaban, pacemaker placement, hypertension and peripheral neuropathy presented to the ED with acute onset altered mental status, expressive aphasia, and right-side weakness, prompting stroke code activation in the ED...The patient was given anti-inhibitor coagulant complex to reverse anticoagulant activity. POC EEG monitoring was initiated in the ED, and the device's artificial intelligence (AI) algorithm alerted the team to suspected continuous seizure activity, for which the patient was loaded with levetiracetam and lacosamide...He was extubated within two days, transferred to the floor after three days in the ICU, and discharged to a skilled nursing facility for further rehabilitation. Although guidelines..."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders • Hypertension

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Northwell Health | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2029 ➔ Nov 2029 | Initiation date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: Jun 2028 ➔ Nov 2028

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Heart Failure

COVID-19-Associated Acquired Hemophilia A With an Exceptionally High Inhibitor Titer: A Case of Remission and Overwhelming Sepsis. (PubMed, Cureus) - "Despite the severity, he achieved complete immunological remission with factor VIII normalization to 343% and inhibitor eradication (0 BU) following treatment with FEIBA, rituximab, cyclophosphamide, and corticosteroids. Yet this case underscores a critical therapeutic paradox: the aggressive immunosuppression necessary for inhibitor eradication carries a substantial risk of infectious mortality. Emerging therapies such as emicizumab may help mitigate this paradox by allowing reduced-intensity immunosuppression, though cost and off-label status currently limit accessibility."

Journal • Cardiovascular • Hematological Disorders • Hemophilia • Hemophilia A • Immunology • Infectious Disease • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Septic Shock

NOVEL ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE REGIMEN FOR MANAGING WARFARIN-ASSOCIATED COAGULOPATHIES (WRMC 2026) - "Kcentra and Balfaxar are the only FDA approved PCC for managing warfarin-associated coagulopathies, but Factor VIII Inhibitor Bypass Activity (FEIBA) is commonly used in practice. The new FEIBA dosing regimen resulted in more individuals achieving a post-FEIBA INR ≤ 1.5. In comparison to other published studies, our population had higher baseline INR values and did not concomitantly receive clotting factor containing products. Our findings support the administration of low-fixed dose FEIBA in the management of warfarin-associated coagulopathies."

Hematological Disorders • Oncology

In brief: Andexanet alfa (Andexxa) withdrawn. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Efficacy and Safety of Fixed Versus Weight-Based Factor Eight Inhibitor Bypassing Activity (FEIBA) for Apixaban or Rivaroxaban Associated Intracranial Hemorrhage (ASHP 2025) - No abstract available

Clinical • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders